CSI Market
Sign In | Register

Sellas Life Sciences Group Inc (SLS) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access SLS Annual Cash Flow →
This cash flow overview for Sellas Life Sciences Group Inc spans from Jun 30 2025 to Jun 30 2026, illustrating how cash generation and usage have shifted across recent reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-18.01
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
Research and Development in Process0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation1.81
Income (Loss) from Equity Method Investments0.00
Paid-in-Kind Interest0.00
Net Income Loss Including Other-
Noncash Rent Expense-
Fair Value Of Shares Mandatorily Redeemable For Cash Upon Exercise Of Warrants-
Fair Value Of Parent Company Common Stock Issued In Exchange For Services-
Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings-
Fair Value Of Common Stock Issued In Exchange For Licensing Rights-
Change In Fair Value Of Contingent Purchase Consideration-
Reclassification Of Warrant Liability Upon Exercise-
Net Liabilities Distributed To Common Stock Holders In Rxi Spin Off Net Of Cash Transferred In Spin Off-
Issuance Of Common Stock In Settlement Of Contingent Purchase Consideration Milestone-
Allocation Of Management Expenses-
Operating Lease Right Of Use Asset Amortization Expense0.15
Increase Decrease In Contract With Customer Liability Net-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable0.14
Increase (Decrease) in Accrued Liabilities0.38
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.74
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-1.49
Discontinued operations0.00
Net Cash flow from Operating Activities-16.43
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Cash Received In Acquisition-
Cash Refunded Paid For Lease Deposit-
Cash Transferred With Spin Off Transaction-
Paymentson Disposal of Productive Assets-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire in Process Research and Development0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock82.98
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Net Proceeds From Exercise Of Common Stock Warrants-
Common Stock Issued In Connection With Espp-
Net Proceeds From Issuance Of Convertible Notes Payable-
Payment of Cash Dividends for Covenanton Longterm Debt-
Stock Subscription Receivable-
Proceeds From Stock Subscription Receivable-
Proceeds From Issuance Of Common Stock And Common Stock Warrants-
Proceeds From Issuance Of Common Stock And Warrants-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities82.98
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-16.43
Total Cash Flow66.55
4 historic quarters locked

Sign in to unlock the full Sellas Life Sciences Group Inc cash flow history.

Sign In Create Free Account

About Sellas Life Sciences Group Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: August 11, 2026
  • Source: sls-20260630.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001390478-26-000012

Figures are derived from filed reports and may be restated. Historical data is subject to revision.